Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes

Geng Chang Yeh, Pao Luh Tao, Hsiu O. Ho, Yung Jin Lee, Yi-Ru Chen, Ming Thau Sheu

研究成果: 雜誌貢獻文章

18 引文 (Scopus)

摘要

In this study, the metabolic ratios of dextromethorphan to dextrorphan (DM/DX) in plasma were calculated at steady state after administering 2 dosage forms (Medicon® and Detusiv®) of DM with different release rates. The urinary metabolic ratio for each subject was also determined based on the total drug concentration in the urine. An analysis of pharmacokinetic parameters for determining the DM metabolic phenotype was conducted. Results demonstrate that double logarithmic correlations between the metabolic ratios based on pharmacokinetic parameters of either AUC0-τss, C max,ss, Cmin,ss, or Cave,ss for Medicon and Detusiv and the urinary metabolic ratios were all significant. Probit plots of the metabolic ratios based on these pharmacokinetic parameters revealed 2 clusters of distribution, representing extensive and intermediate metabolizers. An antimode of 2.0 for total drug based on these pharmacokinetic parameters was determined and correspondingly referred to an antimode of 0.02 for the urinary metabolic ratio to delineate extensive and intermediate metabolizers. This model was also verified to be appropriate when using total plasma concentrations of DM and DX at any time during the period of the dosing interval at steady state to calculate the metabolic ratio for identifying extensive and intermediate metabolizers. Therefore, the metabolic ratio based on the pharmacokinetic parameters of either AUC0-τ,ss, C max,ss, Cmin,ss, or Cave,ss and plasma concentrations of DM and DX in a single blood sample at steady state are proposed as an alternative way to identify phenotypes of CYP2D6.
原文英語
頁(從 - 到)552-564
頁數13
期刊Journal of Biomedical Science
10
發行號5
DOIs
出版狀態已發佈 - 2003

指紋

Dextromethorphan
Pharmacokinetics
Phenotype
Caves
Plasmas
Dextrorphan
Cytochrome P-450 CYP2D6
Dosage Forms
Pharmaceutical Preparations
Blood
Urine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

引用此文

Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes. / Yeh, Geng Chang; Tao, Pao Luh; Ho, Hsiu O.; Lee, Yung Jin; Chen, Yi-Ru; Sheu, Ming Thau.

於: Journal of Biomedical Science, 卷 10, 編號 5, 2003, p. 552-564.

研究成果: 雜誌貢獻文章

Yeh, Geng Chang ; Tao, Pao Luh ; Ho, Hsiu O. ; Lee, Yung Jin ; Chen, Yi-Ru ; Sheu, Ming Thau. / Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes. 於: Journal of Biomedical Science. 2003 ; 卷 10, 編號 5. 頁 552-564.
@article{92c96ea594d94ad387d3b50fff05f179,
title = "Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes",
abstract = "In this study, the metabolic ratios of dextromethorphan to dextrorphan (DM/DX) in plasma were calculated at steady state after administering 2 dosage forms (Medicon{\circledR} and Detusiv{\circledR}) of DM with different release rates. The urinary metabolic ratio for each subject was also determined based on the total drug concentration in the urine. An analysis of pharmacokinetic parameters for determining the DM metabolic phenotype was conducted. Results demonstrate that double logarithmic correlations between the metabolic ratios based on pharmacokinetic parameters of either AUC0-τss, C max,ss, Cmin,ss, or Cave,ss for Medicon and Detusiv and the urinary metabolic ratios were all significant. Probit plots of the metabolic ratios based on these pharmacokinetic parameters revealed 2 clusters of distribution, representing extensive and intermediate metabolizers. An antimode of 2.0 for total drug based on these pharmacokinetic parameters was determined and correspondingly referred to an antimode of 0.02 for the urinary metabolic ratio to delineate extensive and intermediate metabolizers. This model was also verified to be appropriate when using total plasma concentrations of DM and DX at any time during the period of the dosing interval at steady state to calculate the metabolic ratio for identifying extensive and intermediate metabolizers. Therefore, the metabolic ratio based on the pharmacokinetic parameters of either AUC0-τ,ss, C max,ss, Cmin,ss, or Cave,ss and plasma concentrations of DM and DX in a single blood sample at steady state are proposed as an alternative way to identify phenotypes of CYP2D6.",
keywords = "Dextromethorphan, Dextrorphan, Metabolic ratio, Pharmacokinetic parameters, Steady state",
author = "Yeh, {Geng Chang} and Tao, {Pao Luh} and Ho, {Hsiu O.} and Lee, {Yung Jin} and Yi-Ru Chen and Sheu, {Ming Thau}",
year = "2003",
doi = "10.1159/000072383",
language = "English",
volume = "10",
pages = "552--564",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "5",

}

TY - JOUR

T1 - Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes

AU - Yeh, Geng Chang

AU - Tao, Pao Luh

AU - Ho, Hsiu O.

AU - Lee, Yung Jin

AU - Chen, Yi-Ru

AU - Sheu, Ming Thau

PY - 2003

Y1 - 2003

N2 - In this study, the metabolic ratios of dextromethorphan to dextrorphan (DM/DX) in plasma were calculated at steady state after administering 2 dosage forms (Medicon® and Detusiv®) of DM with different release rates. The urinary metabolic ratio for each subject was also determined based on the total drug concentration in the urine. An analysis of pharmacokinetic parameters for determining the DM metabolic phenotype was conducted. Results demonstrate that double logarithmic correlations between the metabolic ratios based on pharmacokinetic parameters of either AUC0-τss, C max,ss, Cmin,ss, or Cave,ss for Medicon and Detusiv and the urinary metabolic ratios were all significant. Probit plots of the metabolic ratios based on these pharmacokinetic parameters revealed 2 clusters of distribution, representing extensive and intermediate metabolizers. An antimode of 2.0 for total drug based on these pharmacokinetic parameters was determined and correspondingly referred to an antimode of 0.02 for the urinary metabolic ratio to delineate extensive and intermediate metabolizers. This model was also verified to be appropriate when using total plasma concentrations of DM and DX at any time during the period of the dosing interval at steady state to calculate the metabolic ratio for identifying extensive and intermediate metabolizers. Therefore, the metabolic ratio based on the pharmacokinetic parameters of either AUC0-τ,ss, C max,ss, Cmin,ss, or Cave,ss and plasma concentrations of DM and DX in a single blood sample at steady state are proposed as an alternative way to identify phenotypes of CYP2D6.

AB - In this study, the metabolic ratios of dextromethorphan to dextrorphan (DM/DX) in plasma were calculated at steady state after administering 2 dosage forms (Medicon® and Detusiv®) of DM with different release rates. The urinary metabolic ratio for each subject was also determined based on the total drug concentration in the urine. An analysis of pharmacokinetic parameters for determining the DM metabolic phenotype was conducted. Results demonstrate that double logarithmic correlations between the metabolic ratios based on pharmacokinetic parameters of either AUC0-τss, C max,ss, Cmin,ss, or Cave,ss for Medicon and Detusiv and the urinary metabolic ratios were all significant. Probit plots of the metabolic ratios based on these pharmacokinetic parameters revealed 2 clusters of distribution, representing extensive and intermediate metabolizers. An antimode of 2.0 for total drug based on these pharmacokinetic parameters was determined and correspondingly referred to an antimode of 0.02 for the urinary metabolic ratio to delineate extensive and intermediate metabolizers. This model was also verified to be appropriate when using total plasma concentrations of DM and DX at any time during the period of the dosing interval at steady state to calculate the metabolic ratio for identifying extensive and intermediate metabolizers. Therefore, the metabolic ratio based on the pharmacokinetic parameters of either AUC0-τ,ss, C max,ss, Cmin,ss, or Cave,ss and plasma concentrations of DM and DX in a single blood sample at steady state are proposed as an alternative way to identify phenotypes of CYP2D6.

KW - Dextromethorphan

KW - Dextrorphan

KW - Metabolic ratio

KW - Pharmacokinetic parameters

KW - Steady state

UR - http://www.scopus.com/inward/record.url?scp=0041421280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041421280&partnerID=8YFLogxK

U2 - 10.1159/000072383

DO - 10.1159/000072383

M3 - Article

C2 - 12928596

AN - SCOPUS:0041421280

VL - 10

SP - 552

EP - 564

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 5

ER -